Eliminate Ghost Peaks in UHPLC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Eliminate Ghost Peaks in UHPLC

Shimadzu has introduced the Ghost Trap™ DS-HP Series Columns which are designed to remove impurities from the solvent and system, enabling highly sensitive and reliable analysis.

These special columns focus on the specific characteristic of the impurities, and their usage can improve the quality of the analytical results dramatically. The Ghost Trap™ DS-HP columns utilise a new packing material with novel carbon technology, available for aqueous as well as for organic solvents. They can eliminate interference peaks not only from the mobile phase and environment but also from HPLC line by locating the column downstream of GE mixer.

Impurities in the HPLC/UHPLC environment often interfere with the real analytes and badly influence the system performance through their appearance as ghost peaks in the chromatogram. Accumulated impurities may elute from the column during gradient elution. Elimination of these contaminations by dedicated columns avoids time-consuming investigations into the background and nature of the contaminants.

Suitable for UHPLC analysis Ghost Trap DS-HP columns offer back pressure tolerance of 100 MPa, well suited to most UHPLC applications in use. They ensure the best performance for high end analysis.

For more information please visit www.shimadzu.eu

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
FindPharma Custom Search

Click here